{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-019467","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.692777+00:00","generated_at":"2026-05-25T21:40:45.036265+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Apogee reports positive interim Phase 1 APG990 data with ~60-day half-life; 2024 net loss $182.1M","bullets":["APG990 demonstrated ~60-day half-life, supporting every 3- and 6-month maintenance dosing; well tolerated up to 1,200 mg.","Combination APG279 (APG777+APG990) Phase 1b vs. DUPIXENT planned for 2025, readout expected H2 2026.","Full-year 2024 net loss $182.1M (vs. $84.0M in 2023); cash, equivalents and marketable securities $731.1M, runway into Q1 2028.","Phase 2 APEX trial for APG777 in atopic dermatitis over-enrolled Part A, Part B initiated; 16-week top-line data expected mid-2025.","R&D expenses $167.9M (up from $68.4M) driven by pipeline advancement and personnel costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-019467","json":"https://secwatch.observer/filing/0001104659-25-019467.json","markdown":"https://secwatch.observer/filing/0001104659-25-019467.md","text":"https://secwatch.observer/filing/0001104659-25-019467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925019467/0001104659-25-019467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925019467/tm258007d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T21:40:45.036265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}